Bank of New York Mellon Corp Sells 13,110 Shares of Veracyte, Inc. $VCYT

Bank of New York Mellon Corp lowered its stake in shares of Veracyte, Inc. (NASDAQ:VCYT) by 3.1% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 413,416 shares of the biotechnology company’s stock after selling 13,110 shares during the period. Bank of New York Mellon Corp’s holdings in Veracyte were worth $13,316,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in VCYT. AEGON ASSET MANAGEMENT UK Plc grew its stake in shares of Veracyte by 19.5% in the fourth quarter. AEGON ASSET MANAGEMENT UK Plc now owns 489,418 shares of the biotechnology company’s stock worth $20,604,000 after purchasing an additional 79,817 shares during the last quarter. William Blair Investment Management LLC raised its position in Veracyte by 16.6% during the 4th quarter. William Blair Investment Management LLC now owns 790,425 shares of the biotechnology company’s stock valued at $33,277,000 after purchasing an additional 112,516 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in Veracyte in the 4th quarter worth approximately $5,475,000. BNP Paribas Financial Markets lifted its holdings in Veracyte by 392.9% in the 4th quarter. BNP Paribas Financial Markets now owns 352,621 shares of the biotechnology company’s stock worth $14,845,000 after buying an additional 281,079 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Veracyte by 12.6% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 138,087 shares of the biotechnology company’s stock worth $5,822,000 after buying an additional 15,451 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Marc Stapley sold 138,051 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.12, for a total value of $6,919,116.12. Following the completion of the transaction, the chief executive officer owned 440,494 shares in the company, valued at $22,077,559.28. The trade was a 23.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Annie Mcguire sold 3,176 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $49.76, for a total transaction of $158,037.76. Following the sale, the executive vice president directly owned 137,240 shares in the company, valued at approximately $6,829,062.40. The trade was a 2.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 206,696 shares of company stock worth $10,079,058. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on VCYT. Morgan Stanley raised their price target on Veracyte from $37.00 to $47.00 and gave the stock an “underweight” rating in a research note on Thursday, July 9th. Wolfe Research began coverage on shares of Veracyte in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $55.00 price objective for the company. Guggenheim raised their target price on shares of Veracyte from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Needham & Company LLC lifted their price objective on Veracyte from $57.00 to $69.00 and gave the company a “buy” rating in a research report on Friday. Finally, Piper Sandler assumed coverage on Veracyte in a research report on Wednesday, July 15th. They issued an “overweight” rating and a $66.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.38.

Key Stories Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.54 per share, above the $0.43 analyst consensus and up from $0.44 a year earlier. Revenue of $150.3 million also exceeded estimates of approximately $144.6 million. Veracyte Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Total revenue increased 15% year over year, while testing revenue rose 19% to $145.7 million, indicating continued demand for Veracyte’s diagnostic testing business. Veracyte Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its full-year 2026 revenue guidance to $590 million-$596 million, above the prior outlook implied by the approximately $585 million analyst consensus. Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Neutral Sentiment: The earnings call and presentation provided additional detail on quarterly performance and the raised 2026 outlook, but investors may be looking for further evidence that growth can accelerate beyond the current guidance range. Veracyte Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite beating quarterly estimates and raising revenue guidance, commentary questioning whether Veracyte is now fully valued suggests the results may not have exceeded the high expectations embedded in the stock. With shares trading at a relatively demanding earnings multiple, investors appear to be taking profits on the news. Is Veracyte Fully Valued After Raising 2026 Revenue Guidance?

Veracyte Stock Down 22.5%

NASDAQ:VCYT opened at $46.32 on Friday. The company’s 50 day moving average price is $53.72 and its 200-day moving average price is $42.32. Veracyte, Inc. has a 52 week low of $22.92 and a 52 week high of $60.91. The stock has a market cap of $3.70 billion, a price-to-earnings ratio of 32.85 and a beta of 1.93.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The company had revenue of $150.32 million during the quarter, compared to analyst estimates of $144.59 million. Veracyte had a net margin of 20.37% and a return on equity of 9.41%. The firm’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.44 EPS. As a group, sell-side analysts anticipate that Veracyte, Inc. will post 1.27 earnings per share for the current year.

Veracyte Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.